Boston Scientific Co. (NYSE:BSX) Stock Position Decreased by PGGM Investments

PGGM Investments lessened its holdings in Boston Scientific Co. (NYSE:BSX) by 20.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 110,580 shares of the medical equipment provider’s stock after selling 28,319 shares during the period. PGGM Investments’ holdings in Boston Scientific were worth $6,393,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bruce G. Allen Investments LLC acquired a new stake in Boston Scientific during the fourth quarter valued at $28,000. Venturi Wealth Management LLC raised its holdings in Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 215 shares in the last quarter. Motco raised its holdings in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 372 shares in the last quarter. Cetera Trust Company N.A bought a new position in Boston Scientific during the fourth quarter valued at about $43,000. Finally, Asset Dedication LLC raised its holdings in Boston Scientific by 42.6% during the third quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 235 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the sale, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,979 shares of company stock worth $3,418,529. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.1 %

Shares of Boston Scientific stock traded down $0.09 during trading hours on Friday, reaching $73.17. 8,786,294 shares of the company’s stock were exchanged, compared to its average volume of 6,225,924. The company has a 50 day moving average of $67.82 and a two-hundred day moving average of $60.56. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $74.39. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The stock has a market cap of $107.35 billion, a P/E ratio of 61.49, a P/E/G ratio of 2.51 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. During the same period in the prior year, the business posted $0.45 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent research reports. Robert W. Baird raised their target price on Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a report on Thursday. Royal Bank of Canada lifted their price objective on Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research note on Thursday. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Raymond James lifted their price objective on Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research note on Thursday. Finally, Evercore ISI boosted their price target on Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $75.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.